LAWRENCEVILLE, N.J., July 11, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that Ronnie T.P. Poon, MD, MS, PhD, FRCS(Edin), FACS, Professor of Surgery at the University of Hong Kong and Lead Asia Pacific Principal Investigator for Celsion's Phase III HEAT Study of ThermoDox® in hepatocellular carcinoma (HCC) will present the clinical trial results at the International Liver Cancer Association 7th Annual Conference being held September 13-15, 2013 in
Washington D.C. The presentation will include data from the HEAT Study post hoc analysis, which suggests positive progression free survival (PFS) and overall survival (OS) in ThermoDox® treated patients when heating cycles from the radiofrequency ablation (RFA) procedure were optimized.
Professor Poon's oral presentation, titled "Phase 3 Randomized, Double-Blind, Dummy-Controlled Trial of Radiofrequency Ablation (RFA) + Lyso-Thermosensitive Liposomal Doxorubicin for Hepatocellular Carcinoma (HCC) Lesions 3-7 cm," will be held Saturday, September 14, 2013 at 12:00 p.m. (local time) in the Plenary Session. ILCA has selected the HEAT Study presentation to be webcast as part of an online educational program of the ILCA 2013 Annual Conference. Dr. Poon's presentation will be made available online after the conference.
The International Liver Cancer Association is the only international organization devoted exclusively to liver cancer research for experts from all related disciplines -- medical, interventional and surgical oncology as well as hepatology. ILCA's Executive Committee consists of Dr. Josep M. Llovet (President); Professor Riccardo Lencioni and Dr. Morris Sherman. Professor Lencioni co-chaired a session devoted to radiofrequency ablation at the 2013 European Conference on Interventional Oncology held in Budapest, Hungary on June 19, 2013 during which he discussed the HEAT Study results
and the emerging post hoc analysis data. Celsion also notes that Professors Lencioni and Poon and Dr. Sherman are principal investigators on the HEAT Study.
Celsion has conducted a comprehensive analysis of the data from the Phase III HEAT Study of ThermoDox® in HCC, also known as primary liver cancer, with key principal investigators, data experts and liver cancer experts including Professors Lencioni and Poon. Emerging data from the HEAT Study post hoc analysis demonstrates that ThermoDox® markedly improves PFS and overall survival in patients if their lesions undergo RFA for 45 minutes or more. These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of approximately 300 patients.
About Celsion Corporation
Celsion is dedicated to the development and commercialization of innovative cancer drugs, including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license or commercialization agreements with leading institutions, including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital,
the Beijing Cancer Hospital and the University of Oxford. For more information on Celsion, visit our website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the significant expense, time, and risk of failure of conducting clinical trials; HEAT Study data is subject to further verification and review by the HEAT Study Data Management Committee; the need for Celsion to evaluate its future development plans; termination of the Technology Development Contract or collaboration between Celsion and HISUN at any time; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion 's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Jeffrey W. Church
Senior Vice President
SOURCE Celsion Corporation